Biotech Startups

A biotechnology company developing patent-pending technology to combat antibiotic resistance by targeting bacterial resistance mechanisms and restoring the effectiveness of existing antibiotics.

1 investor

Nextera develops TCR-Like antibody drug candidates that target disease-specific pHLA antigens for cancer, autoimmune, and inflammatory diseases. It uses protein engineering and phage display technology to build targeted immunotherapies aimed at intracellular disease antigens.

1 investor

NextFerm is a food-tech company that develops fermented vegan proteins intended to improve the flavor and nutritional value of plant-based and alternative protein foods.

1 investor

NextGen Jane runs a longitudinal molecular study of women's menstruation, using an at-home organic cotton tampon collection kit that members mail in to derive genomic insights from uterine samples. The company aims to improve diagnostics and treatment for gynecological conditions such as endometriosis and other menstrual and reproductive health issues.

1 investor

NEXT NEW WORLD is a Japanese company developing silk protein technology, centered on its patented "Karada Silk" process that turns silk into a water-soluble solution while preserving its nano-scale porous structure for adsorption and cosmetic benefits. It applies this material to healthcare, food, cosmetics, and materials markets through joint research with universities and research institutions in Japan and abroad.

1 investor

NextPharma is a European contract development and manufacturing organization (CDMO) providing pharmaceutical development, clinical trials supply, commercial manufacturing and packaging, analytical and microbiological services, and food supplement production. It serves pharmaceutical and nutrition companies developing and manufacturing drugs and food supplements for worldwide markets.

1 investor

Nextrast develops medical imaging contrast agents, including a non-iodine 'blood-pool' agent that stays visible in vasculature and organs for extended imaging windows and an oral agent that darkens the bowel lumen to improve anatomic delineation. Its products target applications such as oncology, cardiovascular disease, inflammatory bowel disease, and small tumor detection.

1 investor

Nexture Bio develops the Doselet, a plant-based dissolvable nanofiber patch for oral nutraceutical delivery, applied to the inner cheek. Its first product delivers 10mg of NAD+ as an alternative to pills or injections for consumer wellness.

1 investor

NF2 Therapeutics (NF2Tx) is a biotech company developing therapies for neurofibromatosis 2 related schwannomatosis (NF2) and related disorders, including an antibody drug conjugate targeting meningiomas and an AAV-based gene therapy for vestibular schwannomas. It works with patients, physicians, and researchers to develop treatments for these rare genetic disorders.

1 investor

Nikon is a manufacturer of imaging products including cameras, lenses, and optical equipment for professional and consumer markets.

1 investor

Nirrin builds optical instruments and analytics software for bioprocess teams to generate measurement data across development and manufacturing workflows. Its systems are designed for deployment in regulated biopharma production and quality environments.

1 investor

1 investor

Nivagen provides drug product development services, guiding pharmaceutical companies through the full lifecycle from concept to commercialization, including traditional NDAs, 505(b)(2)s, and complex generics. The company serves pharmaceutical and biotech firms seeking to bring innovative drug products to market with intellectual property protection and accelerated timelines.

1 investor

NKGen Biotech develops natural killer (NK) cell therapies that work by activating a patient's own immune system. The company operates in the biotech and cell therapy field.

1 investor

NKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.

1 investor

N-Kure focuses on cell therapies, though the page content provided does not include sufficient detail about specific products or customer markets to formulate a complete description.

1 investor

Noah's Farm works on making flavor computable by combining AI, biology, chemistry and flavor science, aiming to preserve flavors at a biological level and reproduce them without relying on climate-vulnerable crops or petroleum. It serves the flavor industry as an alternative to conventional flavor sourcing.

1 investor

Nobias Therapeutics is a clinical-stage drug developer creating small-molecule therapeutics for genetically-defined rare diseases, initially focused on pediatric indications with potential expansion into adult and non-rare conditions. It uses genomic and health datasets alongside relationships with pediatric academic medical centers across North America to advance drug discovery.

1 investor

Noble Biomaterials engineers proprietary antimicrobial and conductive technology platforms for mission-critical applications in consumer, aerospace & defense, and healthcare markets. Its Ionic+ and Circuitex technologies enable odor elimination, infection prevention, EMI shielding, and smart fabric functionality.

1 investor

Nodexus manufactures flow cytometry and particle sorting instruments for life sciences research and cell analysis workflows. The company's systems enable users to analyze, enrich, sort, and dispense particles across specified size ranges using configurable laser and detection channels.

1 investor

Nome offers genetic medicine development as a service, helping rare disease families, foundations, and health systems access and develop personalized n-of-1 genetic therapies. It combines an AI platform with human experts to guide therapeutic programs from treatment design through clinical execution.

1 investor

NonExomics is a drug discovery company that uses a machine learning platform integrating genomics, transcriptomics, and proteomics to identify novel "noncanonical" proteins encoded across the entire human genome, including the previously unstudied 98% "dark genome." It has cataloged hundreds of thousands of such proteins and thousands of novel druggable targets associated with over 1,300 human diseases for therapeutic development.

1 investor

Norachem applies computational and mathematical methods to drug design, drawing on expertise in science, engineering, and business development. The company operates in the computational drug discovery space.

1 investor

Noramco manufactures active pharmaceutical ingredients (APIs) for pharmaceutical customers and partners. The company has been acquired by the Siegfried Group.

1 investor